Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Saved in:
| Title: | Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis. |
|---|---|
| Authors: | Kamal MA; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Kosloski MP; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Lai CH; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Partridge MA; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Rajadhyaksha M; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Kanamaluru V; Sanofi, Bridgewater, NJ, United States., Bansal A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Shabbir A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Shumel B; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Ardeleanu M; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Richards SM; Sanofi, Bridgewater, NJ, United States., Yan H; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Xu CR; Sanofi, Bridgewater, NJ, United States., Rodríguez-Marco A; Sanofi, Madrid, Spain., Xiao J; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Khokhar FA; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Gherardi G; Sanofi, Reading, United Kingdom., Babilonia E; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Maloney J; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Mortensen E; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Akinlade B; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Braunstein N; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Stahl N; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Torri A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Davis JD; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., DiCioccio AT; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2024 Nov 11; Vol. 15, pp. 1466372. Date of Electronic Publication: 2024 Nov 11 (Print Publication: 2024). |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1466372 |
